Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03571568 · ClinicalTrials.gov registry record · Phase 1

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

A Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma, sponsored by BioInvent International AB.

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
20
Study locations

NCT03571568 is a Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by BioInvent International AB. The registered enrollment target is 140 participants, above the 48-participant average among 6 other Indolent B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (192% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03571568, a Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by BioInvent International AB.

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Conditions Studied

Indolent B-Cell Non-Hodgkin Lymphoma

Interventions

  • BIOLOGICAL Rituximab
  • BIOLOGICAL BI-1206
  • BIOLOGICAL Acalabrutinib

Study Locations (20)

Other

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer - Curitiba
  • Ruschel Medicina e Pesquisa Clínica - Rio de Janeiro
  • A.C. Camargo Cancer Center - São Paulo
  • Hospital Amaral Carvalho - São Paulo
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - São Paulo
  • Hospital Israelita Albert Einstein - São Paulo
  • Hospital Samaritano - São Paulo
  • Hospital Sírio-Libanês - São Paulo
  • Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care - Stuttgart
  • Szpital Specjlistyczny - Grudziądz
  • Małopolskie Centrum Medyczne - Krakow
  • Hospital de la Santa Creu i Sant Pau, Dep Hematologia - Barcelona
  • Hospital Universitari Vall d'Hebron - Barcelona
  • Institut Català d'Oncologia, L'Hospitalet de Llobregat - Barcelona

Georgia

  • Emory University Hospital - Atlanta

Kentucky

  • Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405 - Louisville

Estado de Bahia

  • Hospital São Rafael - Salvador

Rio Grande do Sul

  • Hospital de Clínicas de Porto Alegre - Porto Alegre

Hesse

  • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie - Frankfurt am Main

Barcelona

  • Hospital ICO, Trias i Pujol - Badalona

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2018-05-16
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

BioInvent International AB

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03571568

The ClinicalTrials.gov registry entry for NCT03571568 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 6 other Indolent B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (192% higher). The listed sponsor is BioInvent International AB, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Indolent B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT03571568 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Georgia, Kentucky.

Frequently Asked Questions

What is clinical trial NCT03571568 about?

NCT03571568 is a clinical study titled "A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL". Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

What is the current status of trial NCT03571568?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2018-05-16. Estimated completion is 2026-09-30.

What conditions does trial NCT03571568 study?

This clinical trial studies the following conditions: Indolent B-Cell Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT03571568?

The interventions under investigation include: Rituximab (BIOLOGICAL), BI-1206 (BIOLOGICAL), Acalabrutinib (BIOLOGICAL).

Who is sponsoring clinical trial NCT03571568?

This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03571568 being conducted?

This trial has 20 study locations across Georgia, Kentucky, Estado de Bahia, Rio Grande do Sul, Hesse. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Indolent B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Indolent B-Cell Non-Hodgkin Lymphoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.